To describe the clinical characteristics and therapeutic effect of tocilizumab in pediatric patients with Febrile Infection-Related Epilepsy Syndrome (FIRES), highlighting its potential significance in treatment.
Key Findings:
Elevated IL-6 levels were observed in both patients' blood samples, indicating a potential inflammatory response.
Patient 1 received tocilizumab on the 58th day of disease progression, resulting in transient seizure relief but remained unconscious with intermittent seizures.
Patient 2 was treated with tocilizumab on the 7th day of the disease course and showed no seizures or significant cognitive decline during a six-month follow-up.
Seven pediatric FIRES cases treated with tocilizumab have been reported, showing consistent clinical symptoms characterized by focal seizures and status epilepticus.
Interpretation:
Early administration of tocilizumab (within 3 weeks from disease onset) may positively impact the treatment of FIRES, suggesting a need for timely intervention.
Limitations:
The study is based on a small sample size of two patients, which may introduce biases.
Data on the long-term effects and broader applicability of tocilizumab in FIRES are limited.
Conclusion:
The administration of tocilizumab in pediatric FIRES shows potential benefits, particularly when given early in the disease course, warranting further research.
